Drug search by name

Trastuzumab-dkst Intravenous and CHF

Result of checking the interaction of drug Trastuzumab-dkst Intravenous and disease CHF for safety when used together.

Check result:

Trastuzumab-dkst Intravenous <> CHF

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with prior history of heart conditions. Evaluate cardiac function before, during and upon completion of treatment. Discontinue treatment with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further, unless the benefits for the individual patient outweigh the risks.

Trastuzumab-dkst Intravenous

Generic Name: trastuzumab

Brand Name: Herceptin, Kanjinti, Ogivri

Synonyms: Trastuzumab

What is Trastuzumab-dkst Intravenous?